Table 3.
Univariate analysis of factors related to the occurrence of a severe hypersensitivity reaction to cetuximab
| No severe HSR | Severe HSR Grade 3 or 4 | P | |
|---|---|---|---|
| n = 239 | n = 8 | ||
| Age (years), mean ± SD | 61.1 ± 8.9 | 62 ± 12.9 | 0.85 |
| Male | 191 (79.9 %) | 6 (75 %) | 0.67 |
| History of allergy | 28 (11.7 %) | 2 (25 %) | 0.25 |
| Type of cancer | |||
| Head‐and‐neck cancer | 183 (76.6 %) | 6 (75%) | 1 |
| Premedication | |||
| Dexchlorpheniramine | 216 (91.5%) | 8 (100 %) | 1 |
| Corticosteroids | 232 (98.3 %) | 8 (100 %) | 1 |
| Anti‐cetuximab IgE assay | |||
| High | 33 (13.8 %) | 5 (62.5%) | 0.0027 |
HSR, hypersensitivity reaction; SD, standard deviation; IgE, immunoglobulin E.
Data are presented as n (%) unless otherwise specified